News | March 06, 2014

BioZorb Surgical Marker Profiled at BC3 Breast Cancer Conference

Focal Therapeutics BioZorb Tumor Localization Women's Health Oncology Related

March 6, 2014 — The BioZorb 3-D surgical marker improved targeting for radiation therapy by enhancing visualization of the breast cancer lumpectomy cavity. This is according to a presentation at the 2014 Breast Cancer Coordinated Care (BC3) conference in Washington D.C.

The scientific poster reported that substantial advantages were observed when the tissue marker was used with both post-operative radiation boost therapy and partial breast irradiation (PBI).

The study, which involved 22 patients, compared the use of the 3-D tissue marker to traditional tissue landmarks such as seroma and clips as well as post-operative density changes seen on treatment planning CT scans.

"Overall, this tissue marker allowed us to achieve more than a 50 percent reduction in the planned treatment volume," said poster co-author Robert R. Kuske, Jr., M.D., a radiation oncologist at Arizona Breast Cancer Specialists. "With the BioZorb in place we didn't have the guesswork that we have with traditional markers, so we had confidence that we were only irradiating the minimum tissue necessary. This means better results for our patients and also less risk to healthy tissue near the surgical cavity."

Besides the improvement in target volume delineation, the researchers reported that all patients tolerated placement of BioZorb without complications and cosmetic outcomes were excellent.

Previously, there was no standardized method for marking the surgical site of tumor removal, which made post-operative radiation planning difficult. Methods typically used for radiation planning may overestimate the treatment area volume, and may result in excess radiation exposure to normal tissues such as the heart and lungs. This can cause inadvertent complications. 

The open-spiral design of the BioZorb marker incorporates six permanent titanium clips in a fixed 3-D array and provides specific landmarks at the site of the excised tumor. This poster indicates BioZorb marker as useful for radiation treatment planning, patient positioning during treatment and the ability to facilitate advanced methods of radiation treatment, such as respiratory gating.

BioZorb has been used successfully in the United States and New Zealand. It is made of a bioabsorbable material commonly used in other medical devices. It allows the patient's body to absorb the material slowly, so it does not require surgical removal after treatments are completed.

BioZorb received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is available in a range of sizes to accommodate a variety of clinical situations.

For more information: www.focalrx.com

Related Content

GE Healthcare showcases Senographe Pristina with its add-on-biopsy kit at the breast imaging symposium

GE Healthcare showcases Senographe Pristina with its add-on-biopsy kit at the breast imaging symposium in Hollywood, Florida. Photo by Greg Freiherr

Feature | Breast Imaging | April 23, 2019 | By Greg Freiherr
Signs of what the future may look like in women’s health dotted the exhibit floor of the...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used “Deep Learning,“ a form of machine learning, which is a type of artificial intelligence. Graphic courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Artificial Intelligence | April 12, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.
This image depicts ABUS images with QVCAD results

This image depicts ABUS images with QVCAD results.

Feature | Breast Imaging | April 12, 2019
Imaging Technology News spoke with Bob Foley, vice president of sales and marketing of QView Medical, Inc.,
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...